Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study
Abstract Background Hepatitis C virus (HCV) infection prevalence is particularly high in people who inject drugs (PWID), a population that faces many barriers to HCV testing and care. A better understanding of the determinants of access to HCV testing is needed to improve their engagement in the HCV...
Main Authors: | Ilhame Anwar, Cécile Donadille, Camelia Protopopescu, David Michels, Joris Herin, Adélaïde Pladys, Danièle Bader, Patrizia Carrieri, Perrine Roux |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-07-01
|
Series: | Harm Reduction Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12954-023-00841-7 |
Similar Items
-
Correction: Non‑disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community‑based research study
by: Ilhame Anwar, et al.
Published: (2023-08-01) -
Acceptability and Usability of HCV Self-Testing in High Risk Populations in Vietnam
by: Linh Thuy Nguyen, et al.
Published: (2021-02-01) -
Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study
by: Joanne M. Carson, et al.
Published: (2023-09-01) -
Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
by: Vincenzo Messina, et al.
Published: (2020-12-01) -
Hepatitis C Virus Dynamic Transmission Models Among People Who Inject Drugs
by: Woyesa SB, et al.
Published: (2023-02-01)